CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: However, no significant effect was observed for Icaritin-treated normal bone marrow cells (Fig 1B-b).More importantly, we also found that Icaritin was able to potently inhibit the growth of both Imatinib-resistant cells strain and primary imatinib-resistant cells(CD34+) from one CML patient (Fig 1B-c), indicating Icaritin, to a certain extent, may play an role in reversing imatinib-resistance.